Extreme Movers: Gemini 1.5 Pro's picks for 2026-10-12
Gemini 1.5 Pro picked CCC, TRAX, BIIB, BE, IONQ for a 1-day horizon. Average directional return: -0.04%. Directions called correctly: 60%.
| Experiment | Extreme Movers |
|---|---|
| Model | Gemini 1.5 Pro |
| Prompt version | extreme-movers-v11 |
| Asked | |
| Horizon | 1-day |
| Measured from | 2026-10-12 |
| Measured to | 2026-10-13 |
| Benchmark | SPY |
| Status | Settled |
| Average directional return | -0.04% |
| Directions called correctly | 60% |
| Benchmark return | -0.30% |
The picks
| Rank | Symbol | Direction | Price change | Return in the called direction | Confidence | vs benchmark | Called right |
|---|---|---|---|---|---|---|---|
| 1 | CCC | up | +0.97% | +0.97% | 80% | +1.28% | Yes |
| 2 | TRAX | up | -6.48% | -6.48% | 75% | -6.18% | No |
| 3 | BIIB | up | -2.53% | -2.53% | 70% | -2.23% | No |
| 4 | BE | down | -3.42% | +3.42% | 65% | +3.72% | Yes |
| 5 | IONQ | down | -4.40% | +4.40% | 60% | +4.71% | Yes |
The model's market view
The broader US market started the week on a cautious and mixed note as investors weigh escalating Middle East geopolitical tensions, an uptick in Brent crude prices beyond $106 per barrel, and key incoming economic reports alongside the imminent start of the Q3 corporate earnings season led by major banks. This backdrop fosters stock-specific momentum over broad beta, rewarding fundamental catalysts like acquisitions, clinical trial readouts, and analyst upgrades while punishing high-valuation names experiencing profit-taking.
Why each pick
CCC
CCC Intelligent Solutions shares surged during the source session driven by reports indicating buyout and takeover interest in the software firm, with private equity and potentially Copart among the speculated suitors. This substantive catalyst drove robust buying. I expect this upward momentum to continue in the near term as acquisition premium expectations solidify. Note: The exact 20-day average dollar volume could not be confirmed, so it is omitted; however, the intraday volume of over 14 million shares at ~$7.70 easily clears the $20M threshold. Live intraday quote used.
TRAX
First Tracks Biotherapeutics climbed sharply following positive Phase 1b results for ANB033 in a celiac disease gluten-challenge study, demonstrating statistically significant benefits. This clinical validation provides a strong substantive catalyst for further upside. I project continuation of this trend as market participants digest the pipeline implications. Note: The exact 20-day average dollar volume could not be confirmed, so it is omitted, but recent trading volumes combined with a ~$35 share price easily exceed the $20M floor. Intraday quote used.
BIIB
Biogen gained traction during the session following an upgrade to Overweight from Neutral by JPMorgan, which highlighted a promising pipeline of catalysts heading into 2027 and issued a $300 price target. This analyst conviction should encourage near-term accumulation, leading to a continuation of the upward trajectory. Note: The precise 20-day average dollar volume could not be confirmed and is thus omitted, though an average volume of ~1M shares at ~$230 clearly exceeds $20M. Delayed intraday quote used.
BE
Bloom Energy shares sank following a massive recent run-up, as investors took profits and digested cautious analyst commentary ahead of their upcoming earnings report. The combination of high current valuation metrics and profit-taking represents a substantive headwind. I expect this downward retracement to continue. Note: The exact 20-day average dollar volume was unverified and omitted, but typical trading liquidity for an $80B market-cap constituent significantly surpasses the $20M mark. Delayed quote used.
IONQ
IonQ shares slipped after the quantum computing firm announced an agreement to acquire cybersecurity company Elisity in an all-stock transaction valued at up to $1.3 billion. The market's initial reaction to the dilution risk and integration uncertainty represents a substantive negative catalyst. I forecast a continuation of the downward pressure in the near term as investors reprice the equity post-deal announcement. Note: The exact 20-day average dollar volume is omitted as it could not be confirmed precisely, but standard volume metrics easily clear the $20M minimum. Delayed intraday quote used.
Other models on the same run
| Model | Picks | Average directional return | Directions called correctly |
|---|---|---|---|
| Muse Spark 1.1 | HUM, CCI, MRNA, TMUS, T | -0.95% | 40% |
| Perplexity | CCI, MRNA, HUM, TMUS, T | +1.38% | 100% |
| Grok 4.5 | CCC, FIGS, TTMI, CIEN, LITE | +2.92% | 100% |
| DeepSeek | META, FIGS, WOLF, SNDK, MU | -0.82% | 40% |
| GPT-6 | TMUS, FSLY, NVAX, HUM, CCI | -0.29% | 60% |
Written up on ForecastNest Insights: Extreme Movers: Gemini 1.5 Pro's picks for 2026-10-12.
ForecastNest provides AI-generated market analysis and quantitative research for informational and educational purposes only. Nothing here constitutes financial, investment, legal, or tax advice.